Raptor Pharmaceutical to Hold Third Quarter 2013 F

NOVATO, Calif., Oct. 21, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq: RPTP ) today announced that it will release third quarter 2013 financial results after market close on Thursday, November 7, 2013. Raptor management will host a webcast and conference call at 4:30 p.m. EST (1:30 p.m. PST) to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing (877) 870-4263 for domestic callers or (412) 317-0790 for international callers. A live webcast of the conference call will be available online from the investor relations section of the company website at www.raptorpharma.com . After the call, a webcast replay will be available on the Raptor website. A telephone replay of the call will be available by dialing (877) 344-7529 for domestic callers or (412) 317-0088 for international callers, and conference number: 10035938.

About Raptor Pharmaceuticals

Raptor Pharmaceutical Corp. is a biopharmaceutical company focused on developing and commercializing life-altering therapeutics that treat rare, debilitating and often fatal diseases. The company's first product, PROCYSBI ^® (cysteamine bitartrate) delayed-release capsules, is FDA approved for the management of nephropathic cystinosis in adults and children 6 years and older. The European equivalent, PROCYSBI® gastro-resistant hard capsules of cysteamine (as mercaptamine bitartrate), received European Commission approval in September 2013 as an orphan medicinal product for the treatment of proven nephropathic cystinosis for marketing in the European Union (EU). Raptor's pipeline also includes RP103 in a Phase 2/3 trial for Huntington's disease and a Phase 2 trial in nonalcoholic fatty liver disease in children. PROCYSBI was granted orphan designation and exclusivity for nephropathic cystinosis in the U.S. and EU and RP103 has received U.S. orphan drug designation for Huntington's disease. For additional information, please visit www.raptorpharma.com .

Raptor Company Contact: Georgia Erbez Raptor Pharmaceutical Corp. Chief Financial Officer (415) 408-6231 Raptor Investor Contact: Westwicke Partners, LLC Stefan Loren, Ph.D. Managing Director (443) 213-0507 Robert H. Uhl Managing Director (858) 356-5932 Raptor Media Contact: Carolyn Hawley Canale Communications (619) 849-5375